Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs

Epilepsia

Volumn 51, Issue 2, 2010, Pages 274-279

  Belcastro, Vincenzo ^a   Striano, Pasquale ^b   Gorgone, Gaetano ^c   Costa, Cinzia ^a   Ciampa, Clotilde ^d   Caccamo, Daniela ^e   Pisani, Laura R ^e,f   Oteri, Giancarla ^e   Marciani, Maria G ^f   Aguglia, Umberto ^g   Striano, Salvatore ^d   Ientile, Riccardo ^e   Calabresi, Paolo ^a   Pisani, Francesco ^e  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c FATEBENEFRATELLI HOSPITAL   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF MESSINA   (Italy)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

^g UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Folate deficiency; Hepatic enzyme induction; Hyperhomocysteinemia; Oxcarbazepine; Topiramate

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CARBAMAZEPINE; CYANOCOBALAMIN; ETIRACETAM; FOLIC ACID; HOMOCYSTEINE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; TOPIRAMATE;

ADULT; ARTICLE; BRAIN ATROPHY; CONTROLLED STUDY; DNA PURIFICATION; EPILEPSY; FEMALE; GENE; GENETIC POLYMORPHISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MTHFR GENE; PRIORITY JOURNAL; SIDE EFFECT;

ADOLESCENT; ADULT; ANTICONVULSANTS; CARBAMAZEPINE; ENZYME INDUCTION; EPILEPSY; FEMALE; FOLIC ACID; FRUCTOSE; GENOTYPE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PHENOBARBITAL; POLYMORPHISM, GENETIC; TRIAZINES; VITAMIN B 12;

EID: 75649142145     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2009.02303.x     Document Type: Article

References (44)

1. Andreasen AH, Brøsen K, Damkier P. (2007) A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on Cyp3a4. Epilepsia 48:490-496.
2. Annegers JF, Hauser WA, Shirts SB. (1984) Heart disease mortality and morbidity in patients with epilepsy. Epilepsia 25:699-704.
3. Attilakos A, Papakonstantinou E, Schulpis K, Voudris K, Katsarou E, Mastroyianni S, Garoufi A. (2006) Early effect of sodium valproate and carbamazepine monotherapy on homocysteine metabolism in children with epilepsy. Epilepsy Res 71:229-232.
4. Bahrami G, Mirzaeei S, Mohammadi B, Kiani A. (2005) High performance liquid chromatographic determination of topiramate in human serum using UV detection. J Chromatogr B Analyt Technol Biomed Life Sci 822:322-325.
5. Bazzano LA, Reynolds K, Holder KN, He J. (2006) Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 296:2720-2726.
6. Belcastro V, Gaetano G, Italiano D, Oteri G, Caccamo D, Pisani LR, Striano P, Striano S, Ientile R, Pisani F. (2007) Antiepileptic drugs and MTHFR polymorphisms influence hyper-homocysteinemia recurrence in epileptic patients. Epilepsia 48:1990-1994.
7. Bialer M, Doose DR, Murthy B, Curtin C, Wang SS, Twyman RE, Schwabe S. (2004) Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 43:763-780.
8. Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K, NORVIT Trial Investigators. (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354:1578-1588.
9. Caccamo D, Condello S, Gorgone G, Crisafulli G, Belcastro V, Gennaro S, Striano P, Pisani F, Ientile R. (2004) Screening for C677T and A1298C MTHFR polymorphisms in patients with epilepsy and risk of hyperhomocysteinemia. Neuromolecular Med 6:117-126.
10. Chango A, Boisson F, Barbe F, Quilliot D, Droesch S, Pifster M, Fillon-Emery N, Lambert D, Frémont S, Rosenblatt DS, Nicolas JP. (2000) The effect of 677CT and 1298AC mutations on plasma homocysteine and 5,10-methylenetetrahydrofolate reductase activity in healthy subjects. Br J Nutr 83:593-596.
11. Clarke R, Armitage J, Lewington S, Sherliker P, Collins R, on behalf of the B-Vitamin Treatment Trialists' Collaboration. (2006) Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J 151:282-287.
12. Cleary P, Shorvon S, Tallis R. (2004) Late-onset seizures as a predictor of subsequent stroke. Lancet 10:1184-1186.
13. Contin M, Balboni M, Callegati E, Candela C, Albani F, Riva R, Baruzzi A. (2005) Simultaneous liquid chromatographic determination of lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in plasma of patients with epilepsy. J Chromatogr B Analyt Technol Biomed Life Sci 828:113-117.
14. Czeizel AE. (2004) Folic acid and the prevention of neural-tube defects. N Engl J Med 350:2209-2211.
15. Elliott JO, Jacobson MP, Haneef Z. (2007) Cardiovascular risk factors and homocysteine in epilepsy. Epilepsy Res 76:113-123.
16. Gaitatzis A, Carroll K, Majeed A, Sander JW. (2004) The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia 45:1613-1622.
17. Gidal BE, Tamura T, Hammer A, Vuong A. (2005) Blood homocysteine, folate and vitamin B-12 concentrations in patients with epilepsy receiving lamotrigine or sodium valproate for initial monotherapy. Epilepsy Res 64:161-166.
18. Gorgone G, Caccamo D, Pisani LR, Currò M, Parisi G, Oteri G, Ientile R, Rossini PM, Pisani F. (2009) Hyperhomocysteinemia in patients with epilepsy: does it play a role in the pathogenesis of brain atrophy? A preliminary report. Epilepsia 50:33-36.
19. Green PJ, Silverman BW. (1994) Nonparametric regression and generalized linear Models: a roughness penalty approach. Chapman and Hall, Norwell, MA.
20. Hamed SA, Hamed EA, Hamdy R, Nabeshima T. (2007) Vascular risk factors and oxidative stress as independent predictors of asymptomatic atherosclerosis in adult patients with epilepsy. Epilepsy Res 74:183-192.
21. Harden CL, Pennell PB, Koppel BS, Hovinga CA, Gidal B, Meador KJ, Hopp J, Ting TY, Hauser WA, Thurman D, Kaplan PW, Robinson JN, French JA, Wiebe S, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Shafer PO, Le Guen CL, American Academy of Neurology; American Epilepsy Society. (2009) Management issues for women with epilepsy - focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 50:1247-1255.
22. Hassan A, Hunt BJ, O'Sullivan M, Bell R, D'Souza R, Jeffery S, Bamford JM, Markus HS. (2004) Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain 127:212-219.
23. Herrmann W, Herrmann M, Obeid R. (2007) Hyperhomocysteinaemia: a critical review of old and new aspects. Curr Drug Metab 8:17-31.
24. Homocysteine studies collaboration. (2002) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288:2015-2022.
25. Huemer M, Ausserer B, Graninger G, Hubmann M, Huemer C, Schlachter K, Tscharre A, Ulmer H, Simma B. (2005) Hyperhomocysteinemia in children treated with antiepileptic drugs is normalized by folic acid supplementation. Epilepsia 46:1677-1683.
26. Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. (2008) Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc 83:1203-1212.
27. Juenke J, Brown PI, Urry FM, McMillin GA. (2006) Drug monitoring and toxicology: a procedure for the monitoring of levetiracetam and zonisamide by HPLC-UV. J Anal Toxicol 30:27-30.
28. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr, Heart Outcomes Prevention Evaluation (HOPE) Investigators. (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354:1567-1577.
29. McNulty H, Scott JM. (2008) Intake and status of folate and related B-vitamins: considerations and challenges in achieving optimal status. Br J Nutr 99(suppl 3):S48-S54.
30. Mintzer S, Skidmore CT, Abidin CJ, Morales MC, Chervoneva I, Capuzzi DM, Sperling MR. (2009) Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann Neurol 65:448-456.
31. Moat SJ. (2008) Plasma total homocysteine: instigator or indicator of cardiovascular disease? Ann Clin Biochem 45:345-348.
32. Morrow JI, Hunt SJ, Russell AJ, Smithson WH, Parsons L, Robertson I, Waddell R, Irwin B, Morrison PJ, Craig JJ. (2009) Folic acid use and major congenital malformations in offspring of women with epilepsy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 80:506-511.
33. Nilsson L, Tomson T, Farahmand BY, Diwan V, Persson PG. (1997) Cause-specific mortality in epilepsy: a cohort study of more than 9,000 patients once hospitalized for epilepsy. Epilepsia 38:1062-1068.
34. Patsalos PN, Perucca E. (2003) Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2:473-481.
35. Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, Porcellini E, Licastro F. (2005) Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Nutr 82:636-643.
36. Reynolds EH. (2006) Vitamin B12, folic acid, and the nervous system. Lancet Neurol 5:949-960.
37. Sauer J, Mason JB, Choi SW. (2009) Too much folate: a risk factor for cancer and cardiovascular disease? Curr Opin Clin Nutr Metab Care 12:30-36.
38. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA. (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346:476-483.
39. Spence JD. (2007) Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol 6:830-838.
40. Tan TY, Lu CH, Chuang HY, Lin TK, Liou CW, Chang WN, Chuang YC. (2009) Long-term antiepileptic drug therapy contributes to the acceleration of atherosclerosis. Epilepsia 50:1579-1586.
41. Tyagi N, Ovechkin AV, Lominadze D, Moshal KS, Tyagi SC. (2006) Mitochondrial mechanism of microvascular endothelial cells apoptosis in hyperhomocysteinemia. J Cell Biochem 98:1150-1162.
42. Verrotti A, Pascarella R, Trotta D, Giuva T, Morgese G, Chiarelli F. (2000) Hyperhomocysteinemia in children treated with sodium valproate and carbamazepine. Epilepsy Res 41:253-257.
43. Wang G, Dai J, Mao J, Zeng X, Yang X, Wang X. (2005) Folic acid reverses hyper-responsiveness of LPS-induced chemokine secretion from monocytes in patients with hyperhomocysteinemia. Atherosclerosis 179:395-402.
44. Wolff T, Witkop CT, Miller T, Syed SB. (2009) Folic acid supplementation for the prevention of neural tube defects: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 150:632-639.